Recent advances in immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, have shown promising but limited efficacy in recurrent or metastatic HNSCC, underscoring the need for improved patient stratification and combination strategies [21,22]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.